You are here: Industry Insights > Aerie Pharmaceuticals

News List

Aerie Pharmaceuticals Announces Four Appointments firstwordpharma
March 26, 2019
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery,……
Aerie Reports Topline Result from Rhopressa MoA Study americanpharmaceuticalreview
August 16, 2018
Aerie Pharmaceuticals announced topline efficacy results from a double-masked, randomized, placebo-controlled study designed to evaluate the effect of Rhopressa (netarsudil ophthalmic solution) 0.02% on aqueous humor dynamics in patients with open-angle g
Aerie Pharmaceuticals Submits NDA to FDA for Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% drugs
May 17, 2018
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery,
Aerie Pharmaceuticals Names Director of Clinical Research and Drug Safety americanpharmaceuticalreview
February 08, 2017
Aerie Pharmaceuticals, a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment of Huan Sh
Aerie Pharmaceuticals appoints Barry Ivin as Site Director of new manufacturing plant in Ireland cphi-online
February 07, 2017
Aerie Pharmaceuticals has appointed Barry Ivin as Site Director of Aerie’s new manufacturing plant in Athlone, Ireland.